Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
90 EUR | +1.16% | -1.06% | +0.19% |
May. 21 | Sanofi Partners with Microsoft-Backed OpenAI, Formation Bio to Develop Drugs with AI | MT |
May. 21 | Sanofi: cooperation with Formation Bio and OpenAI | CF |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company returns high margins, thereby supporting business profitability.
- The company is in a robust financial situation considering its net cash and margin position.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+0.19% | 121B | - | ||
+37.78% | 705B | C+ | ||
+32.82% | 583B | B | ||
-3.51% | 364B | C+ | ||
+19.94% | 332B | B- | ||
+5.14% | 291B | C+ | ||
+16.64% | 238B | B+ | ||
-4.13% | 210B | A+ | ||
+10.63% | 209B | B- | ||
+9.32% | 169B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- SAN Stock
- SNW Stock
- Ratings Sanofi